ArticleDrug safety2015

PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.

Kristopher J Swiger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.